Correlation Between Ginkgo Bioworks and Aileron Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Ginkgo Bioworks and Aileron Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ginkgo Bioworks and Aileron Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ginkgo Bioworks Holdings and Aileron Therapeutics, you can compare the effects of market volatilities on Ginkgo Bioworks and Aileron Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ginkgo Bioworks with a short position of Aileron Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ginkgo Bioworks and Aileron Therapeutics.

Diversification Opportunities for Ginkgo Bioworks and Aileron Therapeutics

-0.36
  Correlation Coefficient

Very good diversification

The 3 months correlation between Ginkgo and Aileron is -0.36. Overlapping area represents the amount of risk that can be diversified away by holding Ginkgo Bioworks Holdings and Aileron Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aileron Therapeutics and Ginkgo Bioworks is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ginkgo Bioworks Holdings are associated (or correlated) with Aileron Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aileron Therapeutics has no effect on the direction of Ginkgo Bioworks i.e., Ginkgo Bioworks and Aileron Therapeutics go up and down completely randomly.

Pair Corralation between Ginkgo Bioworks and Aileron Therapeutics

Considering the 90-day investment horizon Ginkgo Bioworks Holdings is expected to generate 1.36 times more return on investment than Aileron Therapeutics. However, Ginkgo Bioworks is 1.36 times more volatile than Aileron Therapeutics. It trades about 0.31 of its potential returns per unit of risk. Aileron Therapeutics is currently generating about -0.34 per unit of risk. If you would invest  633.00  in Ginkgo Bioworks Holdings on September 18, 2024 and sell it today you would earn a total of  328.00  from holding Ginkgo Bioworks Holdings or generate 51.82% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Ginkgo Bioworks Holdings  vs.  Aileron Therapeutics

 Performance 
       Timeline  
Ginkgo Bioworks Holdings 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Ginkgo Bioworks Holdings are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent basic indicators, Ginkgo Bioworks sustained solid returns over the last few months and may actually be approaching a breakup point.
Aileron Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Aileron Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Ginkgo Bioworks and Aileron Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Ginkgo Bioworks and Aileron Therapeutics

The main advantage of trading using opposite Ginkgo Bioworks and Aileron Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ginkgo Bioworks position performs unexpectedly, Aileron Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aileron Therapeutics will offset losses from the drop in Aileron Therapeutics' long position.
The idea behind Ginkgo Bioworks Holdings and Aileron Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Other Complementary Tools

Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Fundamental Analysis
View fundamental data based on most recent published financial statements
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance